A Bayesian Estimation Framework for Pharmacogenomics Driven Warfarin Dosing: A Comparative Study

The incorporation of pharmacogenomics information into the drug dosing estimation formulations has been shown to increase the accuracy in drug dosing and decrease the frequency of adverse drug effects in many studies in the literature. In this paper, an estimation framework based on the Bayesian structural equation modeling, which is driven by pharmacogenomics, is proposed. The results show that the model compares favorably with the linear models in terms of prediction and explaining the variations in warfarin dosing.

[1]  O. D. Duncan,et al.  Introduction to Structural Equation Models. , 1977 .

[2]  M. Pirmohamed,et al.  Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy , 2009, Pharmacogenetics and genomics.

[3]  C. V. Van Way.  Patient safety. , 2005, JPEN. Journal of parenteral and enteral nutrition.

[4]  H. McLeod,et al.  Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. , 2006, Trends in pharmacological sciences.

[5]  A. Brix.  Bayesian Data Analysis, 2nd edn , 2005 .

[6]  Hong Yan,et al.  Multivariate hierarchical Bayesian model for differential gene expression analysis in microarray experiments , 2008, BMC Bioinformatics.

[7]  Stephen E Kimmel,et al.  Genetic warfarin dosing: tables versus algorithms. , 2011, Journal of the American College of Cardiology.

[8]  Stephen B Duffull,et al.  A Bayesian Dose-Individualization Method for Warfarin , 2012, Clinical Pharmacokinetics.

[9]  Roderick J. A. Little,et al.  Statistical Analysis with Missing Data: Little/Statistical Analysis with Missing Data , 2002 .

[10]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[11]  David B. Dunson,et al.  Bayesian Structural Equation Modeling , 2007 .

[12]  Willem E. Saris,et al.  Testing Structural Equation Models or Detection of Misspecifications? , 2009 .

[13]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. , 2001, British journal of clinical pharmacology.

[14]  R. Altman,et al.  PharmGKB: understanding the effects of individual genetic variants. , 2008, Drug metabolism reviews.

[15]  Sik-Yum Lee,et al.  Structural equation modelling: A Bayesian approach. , 2007 .

[16]  J. Lindh.  Major determinants of outcome and dosing in warfarin treatment , 2009 .

[17]  D. Greenblatt,et al.  Interaction of Warfarin With Drugs, Natural Substances, and Foods , 2005, Journal of clinical pharmacology.

[18]  Michael R. Mullen,et al.  Structural equation modelling: guidelines for determining model fit , 2008 .

[19]  Daniel E Jonas,et al.  Genetic and clinical factors relating to warfarin dosing. , 2009, Trends in pharmacological sciences.

[20]  T. Ando.  Bayesian predictive information criterion for the evaluation of hierarchical Bayesian and empirical Bayes models , 2007 .

[21]  Li Gong,et al.  VKORC1 pharmacogenomics summary. , 2010, Pharmacogenetics and genomics.

[22]  Xiao-Li Meng,et al.  POSTERIOR PREDICTIVE ASSESSMENT OF MODEL FITNESS VIA REALIZED DISCREPANCIES , 1996 .

[23]  Sik-Yum Lee.  Structural Equation Modeling: A Bayesian Approach , 2007 .

[24]  Shun Higuchi,et al.  Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. , 2009, Pharmacogenomics.

[25]  N. Limdi.  Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation , 2012, Front. Pharmacol..

[26]  R. Altman,et al.  PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. , 2005, Methods in molecular biology.

[27]  J. Kluger,et al.  Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis , 2012, BMC Family Practice.

[28]  P. Bentler,et al.  Cutoff criteria for fit indexes in covariance structure analysis : Conventional criteria versus new alternatives , 1999 .

[29]  M. Shearer,et al.  Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1 , 2008, Journal of thrombosis and haemostasis : JTH.

[30]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[31]  Wenyaw Chan,et al.  Statistical Methods in Medical Research , 2013, Model. Assist. Stat. Appl..

[32]  Howard L McLeod,et al.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.

[33]  D. Schaid,et al.  A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity , 2009, Statistics in medicine.

[34]  M. Loriot,et al.  Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients , 2010, Clinical pharmacology and therapeutics.

[35]  Snigdhansu Chatterjee,et al.  Structural Equation Modeling, A Bayesian Approach , 2008, Technometrics.

[36]  B. Storer,et al.  Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. , 2010, Journal of Molecular Diagnostics.

[37]  John K Kruschke,et al.  Bayesian data analysis. , 2010, Wiley interdisciplinary reviews. Cognitive science.

[38]  A. Borobia,et al.  Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial , 2012, Trials.

[39]  C. Hızel,et al.  Impact of Genetic Factors (CYP2C9, VKORC1 and CYP4F2) on Warfarin Dose Requirement in the Turkish Population , 2013, Basic & clinical pharmacology & toxicology.

[40]  A. Power,et al.  Race and Ethnicity in the Era of Emerging Pharmacogenomics , 2006, Journal of clinical pharmacology.

[41]  C. Sanoski,et al.  Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. , 2002, Chest.

[42]  D. Pennell,et al.  Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.

[43]  Magnus Ingelman-Sundberg,et al.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. , 2004, Trends in pharmacological sciences.

[44]  T. Wienker,et al.  VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation , 2005, Thrombosis and Haemostasis.

[45]  Deborah L Bandalos.  Introduction to structural equation modeling , 2019, Structural Equation Modeling.

[46]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[47]  Yuan-Tsong Chen,et al.  Genetic determinants of warfarin dosing in the Han-Chinese population. , 2009, Pharmacogenomics.

[48]  Paul J Catalano,et al.  An informative Bayesian structural equation model to assess source-specific health effects of air pollution. , 2007, Biostatistics.

[49]  M. Pirmohamed,et al.  Pharmacogenetics of warfarin: current status and future challenges , 2007, The Pharmacogenomics Journal.

[50]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[51]  Jon Emery,et al.  CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis , 2005, Genetics in Medicine.

[52]  Nicole Soranzo,et al.  A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.

[53]  K. Mengersen,et al.  Bayesian Structural Equation Models : A Health Application , 2005 .

[54]  A. Murray,et al.  Pan F, He P, Liu C, Li T, Murray A, Zheng D. Variation of the Korotkoff stethoscope sounds during blood pressure measurement: Analysis using a convolutional neural network. IEEE Journal of Biomedical and Health Informatics , 2017 .

[55]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[56]  Munir Pirmohamed,et al.  Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. , 2010, Blood.

[57]  Sik-Yum Lee,et al.  Bayesian Analysis of Structural Equation Models With Nonlinear Covariates and Latent Variables , 2006, Multivariate behavioral research.